Fig. 4From: Clinical value of detecting IQGAP3, B7-H4 and cyclooxygenase-2 in the diagnosis and prognostic evaluation of colorectal cancerOverall survival rates for patients in different groups. 118 CRC patients from May 2011 to May 2013 were analyzed. We divided patients into several subgroups according to tumor marker levels, T stage, N stage and TNM stage. a The 5-year survival rates in s-IQGAP3 low group were significantly higher than those in s-IQGAP3 high group (s-IQGAP3 low 85.7% vs. s-IQGAP3 high 48.1%, P = 0.007). b The 5-year survival rates in s-B7-H4 low group were significantly higher than those in s-B7-H4 high group (s-B7-H4 low 78.6% vs. s-B7-H4 high 49.0%, P = 0.015). c The 5-year survival rates in s-COX-2 low group were significantly higher than those in s-COX-2 high group (s-COX-2 low 73.8% vs. s-COX-2 high 40.8%, P < 0.001). d The 5-year survival rates in t-IQGAP3 low group were significantly higher than those in t-IQGAP3 high group (t-IQGAP3 low 65.6% vs. t-IQGAP3 high 38.6%, P < 0.001). e The 5-year survival rates in t-B7-H4 low group were significantly higher than those in t-B7-H4 high group (t-B7-H4 low 73.1% vs. t-B7-H4 high 36.4%, P < 0.001). f The 5-year survival rates in t-COX-2 low group were significantly higher than those in t-COX-2 high group (t-COX-2 low 67.3% vs. t-COX-2 high 39.7%, P < 0.001). g The 5-year survival rates in the four T stages were significantly different (T1 77.3% vs. T2 59.4% vs. T3 47.1% vs. T4 33.3%). h The 5-year survival rates in the three N stages were significantly different (N0 68.8% vs. N1 48.7% vs. N2 32.3%). i The 5-year survival rates in the three TNM stages were significantly different (stage I 80.0% vs. stage II 60.7% vs. stage III 41.4%)Back to article page